Contributors
GUILLAUME BEC • Institut de Biologie Mole ´culaire et Cellulaire, CNRS, Universite ´ de
Strasbourg, Strasbourg, France
HOLLY L. BIRCHENOUGH • Faculty of Biology, Medicine and Health, University of
Manchester, Manchester, UK; Wellcome Trust Centre for Cell Matrix Research, University
of Manchester, Manchester, UK
ANDREA BOGUTZKI • Hannover Medical School, Institute for Biophysical Chemistry,
Hannover, Germany
HARLAND E. BRANDON • Department of Chemistry and Biochemistry, Alberta RNA
Research and Training Institute (ARRTI), University of Lethbridge, Lethbridge,
AB, Canada
CHAD A. BRAUTIGAM • Departments of Biophysics and Microbiology, UT Southwestern
Medical Center, Dallas, TX, USA
SE ´ BASTIEN BRU ˆ LE ´ • Plate-forme de Biophysique Mole ´culaire, Institut Pasteur, UMR 3528
CNRS, Paris, France
JOHN E. BURKE • Department of Biochemistry and Microbiology, University of Victoria,
Victoria, BC, Canada; Department of Biochemistry and Molecular Biology, The University
of British Columbia, Vancouver, BC, Canada
UTE CURTH • Hannover Medical School, Institute for Biophysical Chemistry,
Hannover, Germany
GARETH DAVIES • Hit Discovery, Discovery Sciences, R&D BioPharmaceuticals,
AstraZeneca, Alderley Park, UK
BEN J. DAVIS • Vernalis Research, Cambridge, UK
SARAH R. DENNISON • School of Pharmacy and Biomedical Sciences, University of Central
Lancashire, Preston, UK
ERIC ENNIFAR • Institut de Biologie Mole ´culaire et Cellulaire, CNRS, Universite ´ de
Strasbourg, Strasbourg, France
EWA FOLTA-STOGNIEW • W.M. Keck Biotechnology Resource Laboratory, Department of
Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven,
CT, USA
DAVID J. HAMELIN • Department of Biochemistry and Microbiology, University of Victoria,
Victoria, BC, Canada
PAUL E. HEMSLEY • AstraZeneca R&D Discovery Sciences, Cambridge, UK
MATTHEW R. HICKS • Linear Diagnostics Limited, The BioHub, Birmingham, UK
REECE M. HOFFMANN • Department of Biochemistry and Microbiology, University of
Victoria, Victoria, BC, Canada
GEOFFREY A. HOLDGATE • Hit Discovery, Discovery Sciences, R&D BioPharmaceuticals,
AstraZeneca, Alderley Park, UK
PER JEMTH • Department of Medical Biochemistry and Microbiology, BMC, Uppsala
University, Uppsala, Sweden
CHRISTOPHER M. JOHNSON • MRC Laboratory of Molecular Biology, Cambridge, UK
THOMAS A. JOWITT • Faculty of Biology, Medicine and Health, University of Manchester,
Manchester, UK; Wellcome Trust Centre for Cell Matrix Research, University of
Manchester, Manchester, UK
ix
GUILLAUME BEC • Institut de Biologie Mole ´culaire et Cellulaire, CNRS, Universite ´ de
Strasbourg, Strasbourg, France
HOLLY L. BIRCHENOUGH • Faculty of Biology, Medicine and Health, University of
Manchester, Manchester, UK; Wellcome Trust Centre for Cell Matrix Research, University
of Manchester, Manchester, UK
ANDREA BOGUTZKI • Hannover Medical School, Institute for Biophysical Chemistry,
Hannover, Germany
HARLAND E. BRANDON • Department of Chemistry and Biochemistry, Alberta RNA
Research and Training Institute (ARRTI), University of Lethbridge, Lethbridge,
AB, Canada
CHAD A. BRAUTIGAM • Departments of Biophysics and Microbiology, UT Southwestern
Medical Center, Dallas, TX, USA
SE ´ BASTIEN BRU ˆ LE ´ • Plate-forme de Biophysique Mole ´culaire, Institut Pasteur, UMR 3528
CNRS, Paris, France
JOHN E. BURKE • Department of Biochemistry and Microbiology, University of Victoria,
Victoria, BC, Canada; Department of Biochemistry and Molecular Biology, The University
of British Columbia, Vancouver, BC, Canada
UTE CURTH • Hannover Medical School, Institute for Biophysical Chemistry,
Hannover, Germany
GARETH DAVIES • Hit Discovery, Discovery Sciences, R&D BioPharmaceuticals,
AstraZeneca, Alderley Park, UK
BEN J. DAVIS • Vernalis Research, Cambridge, UK
SARAH R. DENNISON • School of Pharmacy and Biomedical Sciences, University of Central
Lancashire, Preston, UK
ERIC ENNIFAR • Institut de Biologie Mole ´culaire et Cellulaire, CNRS, Universite ´ de
Strasbourg, Strasbourg, France
EWA FOLTA-STOGNIEW • W.M. Keck Biotechnology Resource Laboratory, Department of
Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven,
CT, USA
DAVID J. HAMELIN • Department of Biochemistry and Microbiology, University of Victoria,
Victoria, BC, Canada
PAUL E. HEMSLEY • AstraZeneca R&D Discovery Sciences, Cambridge, UK
MATTHEW R. HICKS • Linear Diagnostics Limited, The BioHub, Birmingham, UK
REECE M. HOFFMANN • Department of Biochemistry and Microbiology, University of
Victoria, Victoria, BC, Canada
GEOFFREY A. HOLDGATE • Hit Discovery, Discovery Sciences, R&D BioPharmaceuticals,
AstraZeneca, Alderley Park, UK
PER JEMTH • Department of Medical Biochemistry and Microbiology, BMC, Uppsala
University, Uppsala, Sweden
CHRISTOPHER M. JOHNSON • MRC Laboratory of Molecular Biology, Cambridge, UK
THOMAS A. JOWITT • Faculty of Biology, Medicine and Health, University of Manchester,
Manchester, UK; Wellcome Trust Centre for Cell Matrix Research, University of
Manchester, Manchester, UK
ix